A Breakthrough Approach to Cancer Treatment - U.S. Patent No. 8,315,712

Dec. 3, 2012 - PRLog -- ALBUQUERQUE, N.M. - Cancer-Code Corporation (C3) is proud to announce the issuance of the above U.S. Patent. This patent covers an exciting breakthrough approach to killing cancer through the use of technology, without dependence on chemo or radiation therapies.

The technology in this patent includes our hybrid scientific computer system (HSCS). This is comprised of a signal processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals.  The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system.  Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions.  Confounding electrical signals are stored in a scientific cancer cell signal processor of the HSCS.  The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are re-programmed from cancer cell communication signals.

The objective of this new cancer treatment technology is to apply ultra-low voltage encoded cellular signals (treatment-codes) to rapidly interrupt and thus injure a tumor’s communication system and trigger the cancer cells’ suicide program (apoptosis), while causing no adverse effects to surrounding healthy tissue.

The technology takes advantage of the fact that tumor / cancer cells communicate with one-another.  This makes it possible for the treatment-codes to be transmitted from cancer cell-to-cancer cell, wrecking and shutting-down their cellular electrical communication process. C³’s initial cancer killing trials will focus on breast, lung and prostate cancer tumors implanted on rodents. From this, C³ will proceed to demonstrate this technology on additional cancers.

Affiliates: Neuro Code Tech Holdings, LLC (NCTH, LLC) is a holding company affiliated with C³ in the licensing of intellectual property (IP) to C³ under a Licensing Agreement. The technology is the subject of the above patent, three nonprovisional U.S. patent applications pending and two Peoples Republic of China (PRC) patents pending that are covered in the NCTH, LLC Licensing Agreement.   C³ is the exclusive licensee to manufacture market and sell the patented cancer treatment technology in the U.S. and the PRC. The three pending U.S. patent applications related to killing cancer are:

· U.S. Patent Application Serial No. 12/334,212 entitled “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.

· U.S. Patent Application Serial No. 12/936,778 entitled “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.

· U.S. Patent Application Serial No. 12/812,576 entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”.

C³’s cancer killing technology approach has the potential to replace current cancer chemo and radiation therapy approaches, and represents the dawn of an entirely new treatment approach using tiny encoded signals (codes) to destroy cancer, quickly.  This new and exciting breakthrough is based on the fact that cells communicate. This approach “signals” the cancer cells to kill themselves.

About Cancer-Code Corporation (C³)

C3, located in Albuquerque, NM, is focusing on the development and testing of cancer treatment technology that takes advantage of the fact that all cells have an electrical process and adjacent cells communicate with one another.  The approach of C3 is geared toward disrupting or “wrecking” this cancer cell communication network through tiny pico-sparks, defined as “Codes-of-Death.”  C³ will utilize a Neuro-signaling approach, defined in this Press Release, using recording and archiving systems to record and modify cancer cell communication signals and feed the modified communication  signals  back into  malignant cancer cells to cause apoptosis, which is programmed cell death.  Such a unique treatment modality is expected not to disturb normal adjacent structures and cells. This is a new technology approach to affect killing cancer.  

CANCER-CODE CORPORATION (C³)

117 Bryn Mawr Drive, SE

Albuquerque, New Mexico 87106

Tel. (505) 314-1300     Fax (505) 314-1307

E-mail: cancercode1@gmail.com